Renovaro Stock Price, News & Analysis

Lunai Bioworks Inc. (NASDAQ: RENB) is a biotechnology and technology-focused company that applies artificial intelligence to drug discovery, biodefense, diagnostics, and precision medicine. According to company disclosures and recent press releases, Lunai Bioworks describes itself as an AI-powered drug discovery and biodefense company that is developing platforms to accelerate therapeutic innovation while managing biological and chemical risk. The company has also operated under the Renovaro and Renovaro Biosciences names and has emphasized oncology, neurology, infectious disease, and autoimmune disorders in its stated areas of interest.

The company’s common stock has traded on the Nasdaq Capital Market under the symbol RENB, and, based on SEC filings, a reverse stock split and ticker transition to LNAI were approved and implemented at the corporate level. An 8-K filed on September 24, 2025, states that Lunai Bioworks effected a 1-for-10 reverse stock split of its common stock, with the stock beginning to trade on a reverse-split-adjusted basis on the Nasdaq Capital Market under the symbol “LNAI” as of September 30, 2025. Subsequent 8-K filings dated October 16, 2025, October 30, 2025, November 3, 2025, and November 6, 2025, identify the company as Lunai Bioworks Inc. with its common stock listed on Nasdaq under the symbol LNAI. For historical reference, the RENB symbol is associated with this same corporate issuer as it transitioned through the Renovaro and Lunai Bioworks branding.

Business focus and technology platforms

Company press releases describe Lunai Bioworks as operating at the intersection of biomedical research and advanced machine learning. Through its wholly owned subsidiary BioSymetrics Inc., the company reports that it integrates proprietary datasets, in vivo screening models, and machine learning methods to support drug discovery and diagnostics. Public statements highlight work in precision neurology, oncology, and other high-burden diseases, as well as applications in biodefense and countermeasure development.

In a July 28, 2025 release, Renovaro (now Lunai Bioworks) characterized itself as a precision-medicine technology company and a biotechnology company that uses artificial intelligence and data science to develop therapies and diagnostics in oncology, infectious disease, and autoimmune disorders. The same communication emphasizes intellectual property around federated learning and unbiased drug discovery predictions, describing patents that address integration of heterogeneous biomedical data such as electronic health records, imaging, genomics, and clinical trial data.

Another release dated July 17, 2025, from Renovaro Biosciences describes preclinical work on a dendritic cell therapy platform for pancreatic and other solid tumors. The company reported peer-reviewed data on genetically engineered dendritic cells derived from CD34⁺ hematopoietic stem cells, designed as an allogeneic, "off-the-shelf" approach. The study is presented as demonstrating anti-tumor activity and immune activation in humanized mouse models, and the company positions this platform as part of a broader strategy to develop immune-enhancing therapies that can be adapted across solid tumor indications.

AI-powered drug discovery and precision neurology

Following its merger with BioSymetrics, Lunai Bioworks has emphasized AI-driven platforms for precision neurology and other complex diseases. A September 25, 2025 press release describes Lunai Bioworks as an AI-powered drug discovery company and parent of BioSymetrics, highlighting a biomarker discovery preclinical program in Parkinson's disease. The program uses BioSymetrics’ Augusta Platform and a phenogrouping approach based on a Phenograph knowledge graph and machine learning engine. According to the company, this allows identification of patient subtypes, refinement of disease mechanisms, and development of biomarker-driven therapeutic hypotheses.

BioSymetrics is also described as developing algorithms and digital biomarkers that can support diagnosis, patient stratification, and prediction of treatment response, as well as accelerate therapeutic development. Company communications state that applied AI projects have used large-scale datasets to refine Parkinson's disease subtypes for precision medicine applications. Lunai Bioworks reports that this work spans drug target discovery, validation, and clinical study optimization within its neurology-focused initiatives.

Biodefense and dual-use risk management

Lunai Bioworks repeatedly characterizes itself as a biodefense-focused company in addition to its drug discovery activities. A September 9, 2025 press release describes the launch of a transformer-based platform that embeds biological risk intelligence into large language model pipelines. The company states that this platform uses virtual chemical screening to identify novel compounds as potentially toxic, with the twin goals of expediting therapeutic discovery and addressing the risk that generative AI could be misused to design hazardous biological or chemical agents.

In the same communication, Lunai Bioworks emphasizes a proprietary neurotoxicity dataset derived from thousands of zebrafish-based assays, which it presents as a foundation for its safety intelligence layer. The company positions this technology as supporting both drug discovery AI and biodefense AI markets, and frames its work as aligned with regulatory and policy concerns about AI-enabled biothreats. A separate September 4, 2025 release notes that Lunai Bioworks (doing business as Renovaro at that time) retained American Defense International, Inc. to help align its AI-enabled biomedical data platforms with U.S. government initiatives related to chemical and biological weapons countermeasures.

In an August 8, 2025 release, Renovaro notes that it was mentioned in a RealClearDefense article on AI and biodefense risks. The company describes its strategic focus as including precision neurology platforms and AI-enhanced countermeasures aimed at detecting, mitigating, and responding to emerging biological threats. Across these communications, Lunai Bioworks presents its technology as intended to support national preparedness and biodefense while maintaining a focus on ethical and responsible deployment of AI.

Corporate evolution and naming

SEC filings and press releases document a series of corporate identity changes. Historically, the Polygon description associates the RENB symbol with Enochian Biosciences, a biopharmaceutical company focused on immunotherapy for HIV/AIDS and cancer, headquartered in Los Angeles, California. More recent public information, however, refers to Renovaro Inc., Renovaro Biosciences, and then Lunai Bioworks Inc. as the issuer associated with the RENB ticker.

An 8-K filed on August 26, 2025 states that Renovaro Inc. filed a Certificate of Amendment to change its corporate name to Lunai Bioworks Inc., with the name change effective August 20, 2025. The filing notes that the company’s common stock would continue to trade on Nasdaq under the RENB ticker at that time, with a new CUSIP number resulting from the name change. A subsequent press release dated August 27, 2025 explains that the name Lunai Bioworks Inc. is intended to reflect a strategic focus on AI-powered biodefense, drug discovery, and advanced diagnostics.

Regulatory status and Nasdaq listing

SEC filings confirm that Lunai Bioworks Inc. is incorporated in Delaware and maintains its principal executive offices in Los Angeles, California. The company’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the Nasdaq Capital Market. Multiple 8-K filings in 2025 describe interactions with Nasdaq regarding listing standards.

An 8-K dated August 6, 2025 reports that Nasdaq notified the company in July 2025 that it was not in compliance with Nasdaq Listing Rule 5620(a), which requires an annual meeting of shareholders within twelve months of the end of the fiscal year. The same filing notes that Nasdaq granted an extension until October 31, 2025 for the company to hold its annual meeting. An 8-K dated November 6, 2025 then states that, based on the company’s October 31, 2025 annual meeting, Nasdaq determined that the company had regained compliance with Rule 5620(a) and closed the matter.

Another 8-K filed on October 16, 2025 reports that Nasdaq notified Lunai Bioworks that it had regained compliance with Listing Rule 5550(a)(2), which relates to the minimum bid price requirement. By contrast, an 8-K dated October 30, 2025 notes that Nasdaq issued a notification letter indicating that the company was not in compliance with the $35 million minimum market value of listed securities requirement under Listing Rule 5550(b)(2), and that the company was granted a 180-day period, until April 27, 2026, to regain compliance. The filing explains that if the company does not regain compliance, its securities could be subject to delisting, but also notes that the notice did not have an immediate effect on the listing or trading of the company’s common stock, which continued to trade on the Nasdaq Capital Market.

Subsidiaries and restructuring

Lunai Bioworks’ public disclosures identify at least two notable subsidiaries: BioSymetrics Inc., described as a wholly owned subsidiary focused on biomedical AI and therapeutic discovery, and Gedi Cube B.V., a European subsidiary that has undergone bankruptcy proceedings. A September 8, 2025 press release states that Lunai Bioworks eliminated its legacy subsidiary Gedi Cube B.V., which entered bankruptcy in the Netherlands, as part of a restructuring of its European presence. The company characterizes this step as a move to streamline its structure and focus on growth markets in Europe.

An 8-K filed on September 5, 2025 provides further detail, reporting that the Court of Amsterdam declared Gedi Cube B.V. bankrupt on September 2, 2025 following a voluntary petition. The filing notes that Lunai Bioworks and its other subsidiaries were not filing for bankruptcy protection and would continue to operate their businesses. It also states that management expected to record a material impairment charge related to the bankruptcy and was implementing contingency plans to mitigate any business disruption.

Intellectual property and data infrastructure

In its July 28, 2025 press release, Renovaro (now Lunai Bioworks) highlights multiple U.S. patent allowances related to biomedical AI. These include applications described as covering methods and frameworks for unbiased data in drug discovery predictions and for federated learning with bi-directional data security. The company presents these patents as addressing challenges such as data sparsity, source heterogeneity, and model transferability in biomedical AI, and as enabling integration of diverse data types into standardized pipelines for clinically relevant insights.

The same communication states that these capabilities are intended to support applications in rare disease research, clinical trial optimization, and therapeutic targeting. The company describes its intellectual property portfolio as focused on federated learning architectures that allow AI model training across decentralized healthcare datasets without requiring exchange of sensitive raw data, with the goal of protecting both data sources and model integrity.

Research collaborations and grants

Lunai Bioworks and its subsidiary BioSymetrics report several research collaborations and grant-supported programs. A September 11, 2025 press release announces that BioSymetrics and Brigham and Women’s Hospital received a Small Business Technology Transfer (STTR) grant from the National Institutes of Health’s National Institute on Alcohol Abuse and Alcoholism. The grant supports development of a platform that combines AI-driven behavioral phenotyping with in vivo zebrafish screening to accelerate drug discovery for Alcohol Use Disorder.

The same release notes that the program aims to integrate BioSymetrics’ machine learning tools with experimental phenotyping capabilities to create a scalable discovery engine for Alcohol Use Disorder and to identify novel small molecules as potential therapies. Company statements describe this project as aligned with Lunai Bioworks’ broader approach of combining AI with in vivo biology to identify therapies in areas of significant unmet need.

Historical context

The Polygon description associates the RENB symbol with Enochian Biosciences, formerly Dandrit Biotech USA Inc., describing it as a biopharmaceutical company focused on immunotherapy-based therapies for HIV/AIDS and cancer, including candidates such as ENO-1001, ENO-2001, ENO-4001, ENO-4002, ENO-5001, and ENO-3001. It also notes that Enochian Biosciences was headquartered in Los Angeles, California. While this information provides historical context for the RENB ticker, more recent SEC filings and press releases identify Renovaro and then Lunai Bioworks as the issuer associated with RENB and, later, LNAI.

Investors researching RENB should therefore distinguish between historical information related to Enochian Biosciences and more recent disclosures from Renovaro and Lunai Bioworks. The company’s own communications and SEC filings document a shift toward AI-enabled drug discovery, immuno-oncology, precision neurology, diagnostics, and biodefense, with a corporate name change to Lunai Bioworks Inc. and a subsequent ticker transition to LNAI on the Nasdaq Capital Market.